Bringing the fundamentals into focus…
Back to Clinuvel Pharmaceuticals Limited
How Clinuvel Pharmaceuticals Limited stacks up
CUVL · against 312 other Healthcare companies of similar size
Valuation
98/ 100
Near the top of its peers.
Ranked #11 of 313 · scores higher than 95% of peers
Bars: peers in each 10-point band of the valuation score44 peers with a valuation score of 90–100, including CUVL · Click a bar to see the companies
Why valuation scores 98?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its EBITDA yield and earnings yield, which are stronger than most Healthcare peers.
- Free cash flow yield is not reported, so it is left out of the score.
- higher earnings for the price paid: stronger than 93% of peers. Earnings yield: 8.9% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 98% of peers. EBITDA yield: 35.0% vs peer median 4.0%
Metric by metric
Position: dot = CUVL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | CUVL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 298 reported | 8.9% | -0.4% | 87% | 30% | |
| EBITDA yieldHigher is better · 319 reported | 35.0% | 1.9% | 95% | 50% | |
| Free cash flow yieldHigher is better · 165 reported | Not reported | -9.5% | — | — | 20% |
| Book yieldHigher is better · 302 reported | 74.2% | 53.9% | 64% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around CUVLScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score